Eric Shaff
About Eric Shaff
Eric Shaff is the President and CEO with over 20 years of experience in biotechnology finance, corporate development, and capital markets, having held senior roles at several major pharmaceutical companies.
Professional Title and Current Role
Eric Shaff currently serves as the President and Chief Executive Officer. His leadership role encompasses strategic decision-making, operational oversight, and driving the company's overall vision and mission.
Previous Experience at Seres
Eric Shaff previously held the positions of Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Seres. During his tenure, he played a pivotal role in the company's operations, financial planning, and overall corporate strategy.
Background in Biotechnology and Corporate Finance
With over 20 years of experience in biotechnology finance, corporate development, and capital markets, Eric Shaff has built a robust career in the industry. He has held significant roles at various companies, including Vice President, Corporate Finance at Momenta Pharmaceuticals and Vice President, Finance of Genzyme's Rare Genetic Disease Division. His expertise in corporate finance also extends to his time at Pfizer.
Education and Expertise
Eric Shaff received a Bachelor of Arts degree from the University of Pennsylvania, majoring in political science and economics. He furthered his education with an MBA, concentrating in finance, from the Johnson Graduate School of Management at Cornell University. His academic background laid a strong foundation for his career in biotechnology finance and corporate management.
Board Membership at Sigilon Therapeutics
In addition to his executive roles, Eric Shaff serves on the board of directors of Sigilon Therapeutics, Inc. His role on the board involves contributing to the company’s strategic direction and governance.